REFERENCES
- Bellahcene A, Antoine N, Clausse N, Tagliabue E, Fisher L W, Kerr J M, Jares P, Castronovo V. 1996a. Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels. Lab Invest. 75: 203–210. [INFOTRIEVE]
- Bellahcene A, Kroll M, Liebens F, Castronovo V. 1996b. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res. 11: 665–670. [PUBMED], [INFOTRIEVE]
- Bloch W, Forsberg E, Lentini S, Brakebusch C, Martin K, Krell H W, Weidle U H, Addicks K, Fassler R. 1997. Beta 1 integrin is essential for teratoma growth and angiogenesis. J Cell Biol. 139: 265–278. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Brekken R A, Overholser J P, Stastny V A, Waltenberger J, Minna J D, Thorpe P E. 2000. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60: 5117–5124. [PUBMED], [INFOTRIEVE]
- Byzova T V, Goldman C K, Jankau J, Chen J, Cabrera G, Achen M G, Stacker S A, Carnevale K A, Siemionow M, Deitcher S R, Di, Corleto P E. 2002. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood. 99: 4434–4442. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Byzova T V, Goldman C K, Pampori N, Thomas K A, Bett A J, Shattil S J, Plow E F. 2000a. A Mechanism for Modulation of Cellular Responses to VEGF: Activation of the Integrins. Mol Cell. 6(4)851–860. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Byzova T V, Kim W, Midura R J, Plow E F. 2000b. Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res. 254: 299–308. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Byzova T V, Plow E F. 1998. Activation of αvβ3 on vascular cells controls recognition of prothrombin. J Cell Biol. 143: 2081–2092. [PUBMED], [INFOTRIEVE]
- Cher M L. 2001. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol. 11: 483–488. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Chung L W, Li W, Gleave M E, Hsieh J T, Wu H C, Sikes R A, Zhau H E, Bandyk M G, Logothetis C J, Rubin J S. 1992. Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem. Suppl 16H: 99–105
- Davies M A, Kim S J, Parikh N U, Dong Z, Bucana C D, Gallick G E. 2002. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res. 8(6)1904–1914. [PUBMED], [INFOTRIEVE]
- De S, Chen J, Narizhneva N V, Heston W, Brainard J, Sage E H, Byzova T V. 2003. Molecular pathway for cancer metastasis to bone. J Biol Chem. 278: 39044–39050. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin D J, Witte L, Moore M A, Rafii S. 2000. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 106: 511–521. [PUBMED], [INFOTRIEVE]
- Fata J E, Werb Z, Bissell M J. 2004. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res. 6: 1–11. [PUBMED], [INFOTRIEVE]
- Ferrer F A, Miller L J, Andrawis R I, Kurtzman S H, Albertsen P C, Laudone V P, Kreutzer D L. 1997. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells [see comments]. J Urol. 157: 2329–2333. [PUBMED], [INFOTRIEVE]
- Ferrer F A, Miller L J, Andrawis R I, Kurtzman S H, Albertsen P C, Laudone V P, Kreutzer D L. 1998. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology. 51: 161–167. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ferrer F A, Miller L J, Lindquist R, Kowalczyk P, Laudone V P, Albertsen P C, Kreutzer D L. 1999. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 54: 567–572. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Folkman J. 1997. Angiogenesis and angiogenesis inhibition: An overview. EXS. 79: 1–8. [PUBMED], [INFOTRIEVE]
- Folkman J. 1998. Antiangiogenic gene therapy. Proc Natl Acad Sci USA. 95: 9064–9066. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Gardiner E E, D'Souza S E. 1997. A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1. J Biol Chem. 272: 15474–15480. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Giri D, Ittmann M. 1999. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol. 30: 419–424. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Gleave M E, Hsieh J T, von, Eschenbach A C, Chung L W. 1992. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.. J Urol. 147: 1151–1159. [PUBMED], [INFOTRIEVE]
- Hynes R O. 1992. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell. 69: 11–25. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, Harris A L. 2000. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int. 85: 276–280. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Juliano R L, Varner J A. 1993. Adhesion molecules in cancer: The role of integrins. Curr Opin Cell Biol. 5: 812–818. [PUBMED], [INFOTRIEVE]
- Koeneman K S, Yeung F, Chung L W. 1999. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 39(4)246–261. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Masood R, Cai J, Zheng T, Smith D L, Hinton D R, Gill P S. 2001. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 98: 1904–1913. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Mintz K P, Grzesik W J, Midura R J, Robey P G, Termine J D, Fisher L W. 1993. Purification and fragmentation of nondenatured bone sialoprotein: Evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res. 8: 985–995. [PUBMED], [INFOTRIEVE]
- Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, Kondo Y, Gorrin-Rivas M J, Furumoto K, Kaneda Y, Imamura M. 2000. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther. 7: 1027–1033. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Palecek S P, Loftus J C, Ginsberg M H, Lauffenburger D A, Horwitz A F. 1997. Integrin-ligand binding properties govern cell migration speed through cell—substratum adhesiveness. Nature. 385: 537–540. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Plow E F, Haas T A, Zhang L, Loftus J, Smith J W. 2000. Ligand binding to integrins. J Biol Chem. 275: 21785–21788. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Reiss K, Wang J Y, Romano G, Tu X, Peruzzi F, Baserga R. 2001. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene. 20: 490–500. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Roach H I. 1994. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int. 18: 617–628. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Ruoslahti E. 1996. Integrin signaling and matrix assembly. Tumour Biol. 17: 117–124. [PUBMED], [INFOTRIEVE]
- Sciavolino P J, Abate-Shen C. 1998. Molecular biology of prostate development and prostate cancer. Ann Med. 30: 357–368. [PUBMED], [INFOTRIEVE]
- Smit J W, van der, P G, Vloedgraven H J, Lowik C W, Goslings B M. 1998. Role of integrins in the attachment of metastatic follicular thyroid carcinoma cell lines to bone. Thyroid. 8: 29–36. [PUBMED], [INFOTRIEVE]
- Sokoloff M H, Chung L W. 1998. Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev. 17: 307–315. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Sung V, Stubbs J TI, Fisher L, Aaron A D, Thompson E W. 1998. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the αvβ3 and αvβ5 integrins. J Cell Physiol. 176: 482–494. [PUBMED], [INFOTRIEVE]
- Thalmann G N, Anezinis P E, Chang S M, Zhau H E, Kim E E, Hopwood V L, Pathak S, von, Eschenbach A C, Chung L W. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer [published erratum appears in Cancer Res 54(14):3953]. Cancer Res. 54: 2577–2581. [PUBMED], [INFOTRIEVE]
- Waltregny D, Bellahcene A, Van, Riet I, Fisher L W, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V. 1998. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst. 90: 1000–1008. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Weidner N, Carroll P R, Flax J, Blumenfeld W, Folkman J. 1993. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143: 401–409. [PUBMED], [INFOTRIEVE]
- Zhau H E, Li C L, Chung L W. 2000. Establishment of human prostate carcinoma skeletal metastasis models. Cancer. 88: 2995–3001. [CROSSREF], [PUBMED], [INFOTRIEVE]